Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway

Therapies targeting epidermal growth factor receptor (EGFR) can effectively treat with non-small cell lung cancer (NSCLC), but NSCLC’s drug resistance makes it intractable. Herein, we showed that RU486 metabolite metapristone inhibited the proliferation of various NSCLC cell lines with either wild (...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Shao, Jingwei, Zheng, Guirong, Chen, Hongning, Liu, Jian, Xu, Aixiao, Chen, Fan, Li, Tao, Lu, Yusheng, Xu, Jianguo, Zheng, Ning, Jia, Lee
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5667967/
https://ncbi.nlm.nih.gov/pubmed/29108234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18640
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki